Welcome to our dedicated page for Amesite SEC filings (Ticker: AMST), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Amesite Inc. (NASDAQ: AMST) SEC filings page on Stock Titan provides access to the company’s official regulatory documents as filed with the U.S. Securities and Exchange Commission. These filings offer detailed information about Amesite’s AI-powered NurseMagic™ platform, its focus on home health and post-acute care markets, and the financial and compliance context surrounding its operations.
Investors can review annual reports on Form 10-K and quarterly reports on Form 10-Q to understand how Amesite describes its business model, revenue sources from B2B and B2C NurseMagic™ subscriptions, risk factors, and internal control disclosures. For example, company materials reference filings that discuss revenue growth associated with NurseMagic™ launches, cost management, and the balance between enterprise and individual users.
Current reports on Form 8-K are particularly relevant for tracking material events. In an 8-K dated October 28, 2025, Amesite reported receiving a Nasdaq deficiency notice related to continued listing standards, outlining timelines and potential remediation steps. Another 8-K filed in June 2025 describes a change in the company’s independent registered public accounting firm and references previously disclosed material weaknesses in internal control over financial reporting.
Users can also monitor proxy statements and executive-related disclosures when available, as well as any Form 4 insider transaction reports that may be filed by Amesite’s officers, directors, or significant shareholders. Stock Titan’s platform enhances these documents with AI-powered summaries designed to clarify complex sections of long filings, highlight key business and risk discussions, and make it easier to locate information on topics such as HIPAA compliance, post-acute care strategy, and Nasdaq listing status.
By reviewing Amesite’s SEC filings with these tools, readers can gain a more structured view of how the company presents its AI healthcare solutions, financial condition, and regulatory environment over time.
OMENN GILBERT S reported acquisition or exercise transactions in this Form 4 filing.
Amesite Inc. director Gilbert S. Omenn, through the Gilbert S. Omenn Revocable Trust, received a grant of 6,522 restricted stock units on March 31, 2026. Each unit represents one share of Amesite common stock or its cash equivalent, awarded in lieu of cash director fees based on the quarter-end closing share price. The deferred stock units or cash equivalent will be delivered after he leaves the board or upon an earlier change in control. Following this award, the trust’s indirect holdings reported in this line total 74,783 shares.
Brewer Barbie reported acquisition or exercise transactions in this Form 4 filing.
Amesite Inc. director Barbie Brewer received a grant of 7,541 restricted stock units. These RSUs were awarded as deferred stock units in lieu of cash fees for her board service, with the number of units based on the closing share price on the last day of the quarter.
Each RSU represents the right to receive one share of Amesite common stock or its cash equivalent. The deferred stock units or cash equivalent will be delivered after she completes service on the board or upon an earlier change in control. Following this grant, she holds 30,322 shares or equivalents directly.
Parmer George reported acquisition or exercise transactions in this Form 4 filing.
Amesite Inc. director George Parmer received a grant of 6,522 restricted stock units. These RSUs were issued as deferred stock units in lieu of cash compensation for his board service, with the number of units based on Amesite’s closing share price on the last day of the quarter.
Each RSU represents a contingent right to receive one share of Amesite common stock or its cash equivalent. The deferred stock units or cash equivalent will be delivered after Parmer’s board service ends or upon an earlier change in control. Following this award, he holds 67,887 shares or share-equivalent units directly.
LOSH J MICHAEL reported acquisition or exercise transactions in this Form 4 filing.
Amesite Inc. director J. Michael Losh had 7,880 restricted stock units credited to the J. Michael Losh Irrevocable Qualified Annuity Trust #7. These units were issued as deferred stock units in lieu of cash fees for board service and are tied to the closing share price on the last day of the quarter.
Each restricted stock unit represents a contingent right to receive one share of Amesite common stock or its cash equivalent. The deferred stock units or cash equivalent will be delivered after Mr. Losh’s service on the board ends or upon an earlier change in control. Following this grant, the trust is reported as holding 90,363 deferred/restricted stock units in total, all indirectly associated with Mr. Losh.
Amesite Inc. director Parmer George exercised restricted stock units into common shares, increasing his direct equity stake. On March 7, 2026, 41,322 restricted stock units converted into 41,322 shares of Amesite common stock at a stated price of $0.00 per share. Following the transaction, George directly owned 323,060 shares of common stock. The reported restricted stock units were originally granted on March 7, 2025 and vested on March 7, 2026, with each unit representing a right to receive one share of common stock or its cash equivalent. No open-market purchases or sales were reported in this filing.
Amesite Inc. director Barbie Brewer exercised restricted stock units that had vested into common shares. On March 7, 2026, she converted 41,322 restricted stock units into 41,322 shares of Amesite common stock at a stated price of $0.00 per share as part of her equity compensation.
These restricted stock units were originally granted on March 7, 2025 and vested on March 7, 2026. Following the conversion, Brewer directly holds 135,977 shares of Amesite common stock, and there are no remaining derivative positions from this RSU grant disclosed in the filing.
Amesite Inc. director Gilbert S. Omenn, through the Gilbert S. Omenn Revocable Trust, exercised 41,322 restricted stock units into the same number of Amesite common shares on March 7, 2026. These RSUs were granted on March 7, 2025 and vested one year later. Following the transaction, the trust holds 143,699 shares of Amesite common stock indirectly. This is a compensation-related derivative exercise with no open-market buying or selling disclosed.
Amesite Inc. director J. Michael Losh reported a routine equity compensation event involving restricted stock units held through a trust. On March 7, 2026, the J. Michael Losh Irrevocable Qualified Annuity Trust #7 exercised 41,322 restricted stock units granted on March 7, 2025, converting them into 41,322 shares of Amesite common stock at no cash exercise price. Following the conversion, the trust holds 138,200 shares of common stock indirectly on behalf of Losh. Each restricted stock unit represented a right to receive one share of Amesite common stock or its cash equivalent upon vesting.
Amesite Inc. director J. Michael Losh reported an equity compensation award made through an associated trust. On February 6, 2026, the J. Michael Losh Irrevocable Qualified Annuity Trust #7 received 49,751 restricted stock units (RSUs) of Amesite at a price of $0 per unit.
Each RSU represents a contingent right to receive one share of Amesite common stock or its cash equivalent. The RSUs fully vest on the first anniversary of the grant date, after which the trust will be entitled to the underlying shares or cash value.
Amesite Inc. director Gilbert S. Omenn, through the Gilbert S. Omenn Revocable Trust, reported an award of 49,751 restricted stock units (RSUs) of Amesite Inc. on February 6, 2026, at a price of $0 per unit.
Each RSU represents a contingent right to receive one share of Amesite common stock and/or the cash equivalent of one share. The RSUs fully vest on the first anniversary of the grant date, and the trust holds 49,751 derivative securities after this transaction.